How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease

Sepiso K Masenga; Selam Desta; Mark Hatcher; Annet Kirabo; Dexter L Lee

doi:10.1016/j.crphys.2024.100133

How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease

Curr Res Physiol. 2024 Nov 14:8:100133. doi: 10.1016/j.crphys.2024.100133. eCollection 2025.

Authors

Sepiso K Masenga^{1

2}, Selam Desta^{3

4}, Mark Hatcher⁴, Annet Kirabo^{3

5

6

2}, Dexter L Lee⁴

Affiliations

¹ HAND Research Group, School of Medicine and Health Sciences, Mulungushi University, Livingstone Campus, Zambia.
² Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴ Department of Physiology and Biophysics, College of Medicine, Howard University, Washington, DC, USA.
⁵ Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁶ Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, TN, USA.

Abstract

Chronic kidney disease (CKD) is a major risk factor for death in adults. Inflammation plays a role in the pathogenesis of CKD, but the mechanisms are poorly understood. Peroxisome proliferator-activated receptor alpha (PPAR-α) is a nuclear receptor and one of the three members (PPARα, PPARβ/δ, and PPARγ) of the PPARs that plays an important role in ameliorating pathological processes that accelerate acute and chronic kidney disease. Although other PPARs members are well studied, the role of PPAR-α is not well described and its role in inflammation-mediated chronic disease is not clear. Herein, we review the role of PPAR-α in chronic kidney disease with implications for the immune system.

Keywords: Chronic kidney disease; Immunity; Inflammation; PPAR-α; Peroxisome proliferator-activated receptors.

Publication types

Review